CLINICAL RESEARCH: CARDIAC IMAGING
The Relationship Between Plasma Osteoprotegerin Levels and Coronary Artery Calcification in Uncomplicated Type 2 Diabetic Subjects
Dhakshinamurthy Vijay Anand, MBBS, MRCP*, , ,*,
Avijit Lahiri, MBBS, MSc, MRCP, FACC, FESC*,
Eric Lim, MBChB, MA, MRCP*,
David Hopkins, BSc, MBChB, FRCP and
Roger Corder, PhD, MRPharmS
* Cardiac Imaging and Research Centre, Wellington Hospital, London, United Kingdom
William Harvey Research Institute, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, United Kingdom
Department of Cardiology, Royal Free Hospital, London, United Kingdom
Department of Endocrinology, Kings College Hospital, London, United Kingdom.
Manuscript received July 10, 2005;
revised manuscript received November 24, 2005,
accepted December 5, 2005.
* Reprint requests and correspondence: Dr. Dhakshinamurthy Vijay Anand, Cardiac Imaging and Research Centre, Wellington Hospital (South), Wellington Road, St. John’s Wood, London, NW8 9LE, United Kingdom. (Email: vdanand{at}hotmail.com).
OBJECTIVES: This study sought to prospectively evaluate the relationship between plasma osteoprotegerin (OPG), inflammatory biomarkers (high-sensitivity C-reactive protein [hs-CRP], interleukin-6 [IL-6], coronary artery calcification (CAC), and cardiovascular events in patients with type 2 diabetes.
BACKGROUND: Arterial calcification is a prominent feature of atherosclerosis and is associated with an increased risk of cardiovascular events. Osteoprotegerin is a cytokine that has recently been implicated in the regulation of vascular calcification.
METHODS: A total of 510 type 2 diabetic patients (53 ± 8 years; 61% male) free of symptoms of cardiovascular disease were evaluated by CAC imaging. Risk factors, hs-CRP, IL-6, and OPG levels were measured. Patients were followed up for cardiovascular events (cardiac death, myocardial infarction, acute coronary syndrome, late revascularization, and nonhemorrhagic stroke).
RESULTS: Significant CAC (>10 Agatston units) was seen in 236 patients (46.3%); OPG was significantly elevated in patients with increased CAC. In multivariable analyses, OPG retained a strong association with elevated CAC scores after adjustment for age, gender, and other risk factors (odds ratio = 2.84, 95% confidence interval 2.2 to 3.67; p < 0.01). Sixteen cardiovascular events occurred during a mean follow-up of 18 ± 5 months. The waist-to-hip ratio, United Kingdom Prospective Diabetes Study (UKPDS) risk score, OPG level, and CAC score were significant predictors of time to cardiovascular events in a univariate Cox proportional hazards model. In the multivariate model, the CAC score was the only independent predictor of adverse events. Levels of hs-CRP and IL-6 were related to neither the extent of CAC nor short-term events.
CONCLUSIONS: A high proportion of asymptomatic diabetic patients have significant subclinical atherosclerosis. Of the biomarkers studied, only OPG predicted both subclinical disease and near-term cardiovascular events. Therefore, measurement of OPG merits further investigation as a simple test for identifying high-risk type 2 diabetic patients.
|
Abbreviations and Acronyms
| | AU = Agatston units | | CAC = coronary artery calcification | | CAD = coronary artery disease | | EBCT = electron beam computed tomography | | hs-CRP = high-sensitivity C-reactive protein | | IL = interleukin | | IQR = interquartile range | | OPG = osteoprotegerin | | OR = odds ratio | | UKPDS = United Kingdom Prospective Diabetes Study |
|
This article has been cited by other articles:
|
|
|
|
 
M. Svensson, D. O. Dahle, G. Mjoen, G. Weihrauch, H. Scharnagl, H. Dobnig, W. Marz, A. Jardine, B. Fellstrom, and H. Holdaas
Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study
Nephrol. Dial. Transplant.,
December 15, 2011;
(2011)
gfr694v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Scialla, M. B. Leonard, R. R. Townsend, L. Appel, M. Wolf, M. J. Budoff, J. Chen, E. Lustigova, C. A. Gadegbeku, M. Glenn, et al.
Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol.,
November 1, 2011;
6(11):
2612 - 2619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Koulaouzidis and M. Henein
Coronary Calcification and Hormones
Angiology,
October 1, 2011;
62(7):
554 - 564.
[Abstract]
[PDF]
|
|
|
|
|
|
|
X. Lin, X. Han, T. Kawai, and M. A. Taubman
Antibody to Receptor Activator of NF-{kappa}B Ligand Ameliorates T Cell-Mediated Periodontal Bone Resorption
Infect. Immun.,
February 1, 2011;
79(2):
911 - 917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Reinhard, M. Lajer, M.-A. Gall, L. Tarnow, H.-H. Parving, L. M. Rasmussen, and P. Rossing
Osteoprotegerin and Mortality in Type 2 Diabetic Patients
Diabetes Care,
December 1, 2010;
33(12):
2561 - 2566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Venuraju, A. Yerramasu, R. Corder, and A. Lahiri
Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity
J. Am. Coll. Cardiol.,
May 11, 2010;
55(19):
2049 - 2061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Camozzi, F. Sanguin, N. Albigier, C. Scaroni, F. Mantero, M. Zaninotto, A. Frigo, M. Piccolo, and G. Luisetto
Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome
Eur. J. Endocrinol.,
January 1, 2010;
162(1):
85 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Morena, A.-M. Dupuy, I. Jaussent, H. Vernhet, G. Gahide, K. Klouche, A.-S. Bargnoux, C. Delcourt, B. Canaud, and J.-P. Cristol
A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients
Nephrol. Dial. Transplant.,
November 1, 2009;
24(11):
3389 - 3397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Sigrist, A. Levin, L. Er, and C. W. McIntyre
Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification
Nephrol. Dial. Transplant.,
October 1, 2009;
24(10):
3157 - 3162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nybo, S. P. Johnsen, C. Dethlefsen, K. Overvad, A. Tjonneland, J. O. L. Jorgensen, and L. M. Rasmussen
Lack of Observed Association between High Plasma Osteoprotegerin Concentrations and Ischemic Stroke Risk in a Healthy Population
Clin. Chem.,
December 1, 2008;
54(12):
1969 - 1974.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nybo and L. M Rasmussen
The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review
Eur. J. Endocrinol.,
November 1, 2008;
159(5):
603 - 608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Speer, B. Cs. Fekete, T. El Hadj Othmane, T. Szabo, J. Egresits, E. Fodor, I. Kiss, A. G. Logan, J. Nemcsik, A. Szabo, et al.
Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients
Nephrol. Dial. Transplant.,
October 1, 2008;
23(10):
3256 - 3262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev.,
April 1, 2008;
29(2):
155 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-H. Gannage-Yared, C. Yaghi, B. Habre, S. Khalife, R. Noun, M. Germanos-Haddad, and V. Trak-Smayra
Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study
Eur. J. Endocrinol.,
March 1, 2008;
158(3):
353 - 359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sultan, A. Avignon, F. Galtier, C. Piot, D. Mariano-Goulart, A. M. Dupuy, and J. P. Cristol
Osteoprotegerin, Thiazolidinediones Treatment, and Silent Myocardial Ischemia in Type 2 Diabetic Patients
Diabetes Care,
March 1, 2008;
31(3):
593 - 595.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Omland, T. Ueland, A. M. Jansson, A. Persson, T. Karlsson, C. Smith, J. Herlitz, P. Aukrust, M. Hartford, and K. Caidahl
Circulating Osteoprotegerin Levels and Long-Term Prognosis in Patients With Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
February 12, 2008;
51(6):
627 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. V. Anand, E. Lim, D. Darko, P. Bassett, D. Hopkins, D. Lipkin, R. Corder, and A. Lahiri
Determinants of Progression of Coronary Artery Calcification in Type 2 Diabetes: Role of Glycemic Control and Inflammatory/Vascular Calcification Markers
J. Am. Coll. Cardiol.,
December 4, 2007;
50(23):
2218 - 2225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Nellemann, L. C. Gormsen, J. Dollerup, O. Schmitz, C. E. Mogensen, L. M. Rasmussen, and S. Nielsen
Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria
Diabetes Care,
December 1, 2007;
30(12):
3122 - 3124.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Mangan, A. V. Campenhout, C. Rush, and J. Golledge
Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-{alpha} associated with induction of angiopoietin-2
Cardiovasc Res,
December 1, 2007;
76(3):
494 - 505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Avignon, A. Sultan, C. Piot, D. Mariano-Goulart, J.-F. Thuan dit Dieudonne, J. P. Cristol, and A. M. Dupuy
Osteoprotegerin: A Novel Independent Marker for Silent Myocardial Ischemia in Asymptomatic Diabetic Patients
Diabetes Care,
November 1, 2007;
30(11):
2934 - 2939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hsia, G. Heiss, H. Ren, M. Allison, N. C. Dolan, P. Greenland, S. R. Heckbert, K. C. Johnson, J. E. Manson, S. Sidney, et al.
Calcium/Vitamin D Supplementation and Cardiovascular Events
Circulation,
February 20, 2007;
115(7):
846 - 854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
